|
|
|
||
(State or other jurisdiction
of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
◻
|
•
|
the multiple effects of the impact of public health crises and epidemics/pandemics, such as the novel strain of COVID-19
(coronavirus) which the financial magnitude cannot be currently estimated;
|
•
|
changes as the result of government enacted national healthcare reform;
|
•
|
changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification
and/or enrollment status, including the Medicare reimbursement reduction scheduled to become effective January 1, 2021;
|
•
|
revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
|
•
|
business and regulatory conditions including federal and state regulations;
|
•
|
governmental and other third-party payor inspections, reviews, investigations and audits, which may result in sanctions or
reputational harm and increased costs;
|
•
|
compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information,
and associated fines and penalties for failure to comply;
|
•
|
changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the
deductibles and co-pays owed by patients;
|
•
|
revenue and earnings expectations;
|
•
|
legal actions, which could subject us to increased operating costs and uninsured liabilities;
|
•
|
general economic conditions;
|
•
|
availability and cost of qualified physical therapists;
|
•
|
personnel productivity and retaining key personnel;
|
•
|
competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and
thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
|
•
|
competitive environment in the industrial injury prevention business, which could result in the termination or non-renewal of
contractual service arrangements and other adverse financial consequences for that service line;
|
•
|
acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the
acquired businesses;
|
•
|
maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
|
•
|
a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and
reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
|
•
|
maintaining adequate internal controls;
|
•
|
maintaining necessary insurance coverage;
|
•
|
availability, terms, and use of capital; and
|
•
|
weather and other seasonal factors.
|
U.S. PHYSICAL THERAPY, INC.
|
|||||||
Dated: December 9, 2020
|
By:
|
/s/ CAREY HENDRICKSON
|
|||||
Carey Hendrickson
|
|||||||
Chief Financial Officer
|
|||||||
(duly authorized officer and principal financial and accounting officer)
|